Approval · Notice of Compliance 28425 · 2022
TRI-SOLFEN: Notice of Compliance 28425
Issued June 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28425
- Date
- June 21, 2022
- Company
- Dechra LtdSkipton, North Yorkshire, United Kingdom
- Product type
- Veterinary
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRI-SOLFEN | 02528223 | Marketed |
Medicinal ingredients
- BUPIVACAINE HYDROCHLORIDE 4.2 MG per ML
- CETRIMIDE 5 MG per ML
- EPINEPHRINE BITARTRATE 0.025 MG per ML
- LIDOCAINE HYDROCHLORIDE 40.6 MG per ML